Company
United StatesPublic company, NASDAQ: VERAVera Therapeutics, Inc. (NASDAQ: VERA), Brisbane, CA – FDA Inspections
Inspection records and compliance data for Vera Therapeutics, Inc. in Brisbane, CA. 1 FDA inspection on record, 1 Form 483, last inspected March 02, 2026. Publicly traded as NASDAQ: VERA.
Company Profile
This profile covers Vera Therapeutics, Inc. based in Brisbane, CA, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 1
- Warning letters
- 0
Inspected March 2, 2026.
Most cited issue areas
- General responsibilities of sponsors1 inspection
- Investigator statement (FDA 1572)1 inspection
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| March 2, 2026 | Not classified | Human Drugs · Bioresearch Monitoring: Human Drugs | 1307182 |
FDA documents
Form 483s (1)
People (1)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Scilex Pharmaceuticals Inc.
Ascendis Pharma LLC
Zev Wainberg, M.D.
David M. Scarpino, M.D.
Protagonist Therapeutics Inc
Molecular Imaging Program at Stanford
McKesson Corporation Headquarters
Amitabha Mazumder, M.D.
Comparative Biosciences, Inc
Stanford University School of Medicine Radioactive Drug Research Committee
Company Information
Name
Vera Therapeutics, Inc.
Stock ticker
VERA
Exchange
NASDAQ
Share price
$29.04
Market cap
$2.1B
Price as of
November 13, 2026
FEI Number
3037451774
Address
2000 Sierra Point Pkwy Ste 1200, Brisbane, CA 94005-1806, United States
Country
United States
ID: 7710a3a0-225b-4f3e-8dd3-6e42f78d4e59